<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897130</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003943-55</org_study_id>
    <nct_id>NCT00897130</nct_id>
  </id_info>
  <brief_title>5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)</brief_title>
  <acronym>MDSAZA0706</acronym>
  <official_title>Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Udine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cremona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mantova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Azacitidine will be given at a dose of 75 mg/sqm (s.c) daily for 5 consecutive days every 28&#xD;
      days (every month) for a total of 8 courses to low risk MDSs according to IPSS scoring&#xD;
      system. In fact, several studies produced high rates of trilineage responses, reduces the&#xD;
      risk of progression to acute myeloid leukemia (AML) in high-risk MDS and improves the quality&#xD;
      of life (QoL). The use of 5-Aza in the earlier phases of MDS could reduce the proliferative&#xD;
      advantage of MDS clone and favour the regrowth of normal hematopoiesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs. When administered at a&#xD;
      dose of 75mg/m2/day subcutaneously for 7 days, every 28 days (every month), 5-Aza produces&#xD;
      high rates of trilineage responses, reduces the risk of progression to AML in high-risk MDS&#xD;
      and improves the QoL. The use of 5-Aza in the earlier phases of MDS could reduce the&#xD;
      proliferative advantage of MDS clone and favour the regrowth of normal hematopoiesis. Other&#xD;
      doses or schedules could improve its efficacy. Gene expression profile studies in MDS&#xD;
      patients who are sensitive or resistant to 5-AZA are lacking and data coming from these&#xD;
      studies could be useful to clarify the mechanisms of 5-azacitidine and optimize the therapy.&#xD;
&#xD;
      Objectives of the study&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        -  To evaluate the efficacy (hematologic response) and toxicity of 5-Aza five days monthly&#xD;
           treatment schedule in patients with low-risk MDS (IPSS 0-INT1)&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To evaluate QoL by the FACT-An questionnaire&#xD;
&#xD;
        -  To evaluate time to progression of MDS;&#xD;
&#xD;
        -  To evaluate the gene expression profile of MDS patients sensitive or resistant to 5-AZA;&#xD;
&#xD;
        -  To evaluate oncostatin M, interleukin-6 and interleukin-11 levels in the responders and&#xD;
           non responders.&#xD;
&#xD;
      Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days&#xD;
      every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted as&#xD;
      follows:&#xD;
&#xD;
      Patients' care and other medications&#xD;
&#xD;
        -  RBC are transfused to maintain a Hb level &gt; 90 g/L, or whenever indicated.&#xD;
&#xD;
        -  Platelets are transfused if platelet count is &lt; 20 x 109/L, or whenever indicated.&#xD;
&#xD;
        -  EPO is not allowed during the trial time (8 months= 8 courses of 5-AZA therapy)&#xD;
&#xD;
        -  Granulocyte or granulocyte-monocyte colony stimulating factor (G-CSF or GM-CSF) are&#xD;
           allowed in case of severe neutropenia and/or systemic infection.&#xD;
&#xD;
        -  Antibiotics and antifungals per os are given in prophylaxis if neutrophils &lt;0.5 x 109&#xD;
           /L.&#xD;
&#xD;
        -  Antibiotics are given i.v. in case of fever (&gt; 38°C for &gt; 24 h) or whenever indicated.&#xD;
&#xD;
        -  Antifungals are given i.v. in case of fever persisting for more than 5 days of&#xD;
           antibiotics i.v. or whenever indicated.&#xD;
&#xD;
        -  Other experimental drugs or agents are not allowed.&#xD;
&#xD;
        -  If another experimental drug or agent will be administered, the patient must discontinue&#xD;
           the treatment with 5-AZA, and goes off-study.&#xD;
&#xD;
      Definition of Response&#xD;
&#xD;
      The response to treatment will be assessed according to IWG 2006 criteria, as reported by&#xD;
      Cheson et al.(28) (Appendix F)&#xD;
&#xD;
      Response criteria for altering natural history of MDS:&#xD;
&#xD;
        -  Complete remission (CR) Bone marrow: ≤5% myeloblasts with normal maturation of all cell&#xD;
           lines Persistent dysplasia will be notes Peripheral blood: Hgb ≥ 11g/dl, Platelets ≥ 100&#xD;
           x 109/l, Neutrophils ≥ 1.0 x 109/l, Blasts 0%&#xD;
&#xD;
        -  Partial remission (PR)&#xD;
&#xD;
      All CR criteria if abnormal before treatment except:&#xD;
&#xD;
      Bone marrow blasts decreased by ≥50% over pretreatment but still &gt;5% Cellularity and&#xD;
      morphology not relevant&#xD;
&#xD;
        -  Marrow CR Bone marrow ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment&#xD;
           Peripheral blood: if HI response, they will be noted in addition to marrow CR&#xD;
&#xD;
        -  Stable disease Failure to achieve at least PR, but no evidence of progression for &gt;8&#xD;
           weeks&#xD;
&#xD;
        -  Failure Death during treatment or disease progression characterized by worsening of&#xD;
           cytopenias, increase in the percentage bone marrow blasts, or progression to a more&#xD;
           advanced MDS FAB subtype than pretreatment.&#xD;
&#xD;
        -  Relapse after CR or PR&#xD;
&#xD;
      At least one of the following:&#xD;
&#xD;
        -  Return to pretreatment bone marrow blast percentage&#xD;
&#xD;
        -  Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets&#xD;
&#xD;
        -  Reduction in Hgb concentration by ≥ 1.5 g/dl or transfusion dependence&#xD;
&#xD;
             -  Cytogenetic Response&#xD;
&#xD;
                  1. Complete Disappearance of the chromosomal abnormality without appearance of&#xD;
                     new ones&#xD;
&#xD;
                  2. Partial At least 50% reduction of the chromosomal abnormality&#xD;
&#xD;
             -  Disease progression For patients with Less than 5% blasts: ≥50% increase in blasts&#xD;
                to &gt; 5% blasts 5%-10% blasts: ≥50% increase to &gt;10% blasts 10%-20% blasts: ≥ 50%&#xD;
                increase to &gt; 20% blasts 20%-30% blasts: ≥50% increase to &gt;30% blasts Any of the&#xD;
                following At least 50% decrement from maximum remission/response in granulocytes or&#xD;
                platelets Reduction in Hgb by ≥ 2g/dl Transfusion dependence&#xD;
&#xD;
      Survival&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Overall: death from any cause Event free: failure or death from any cause PFS: disease&#xD;
      progression or death form MDS DFS: time to relapse Cause-specific death: death related to MDS&#xD;
&#xD;
      Response criteria for hematologic improvement (HI)&#xD;
&#xD;
        -  Erythroid response (HI-E) (pretreatment, &lt;11 g/dl) Hgb increase by ≥1.5 g/dl Relevant&#xD;
           reduction on units of RBC transfusion by an absolute number of at least 4 RBC&#xD;
           transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8&#xD;
           weeks. Only RBC transfusions given for a Hgb of ≤ 9.0 g/dl pretreatment will count in&#xD;
           the RBC transfusion response evaluation&#xD;
&#xD;
        -  Platelet response (HI-P)(pretreatment, &lt;100 x 109/l) Absolute increase of ≥ 30 x 109/l&#xD;
           for patients starting with &gt;20 x 109/l platelets Increase from &lt; 20 x 109/l to &gt;20 x&#xD;
           109/l and by at least 100%&#xD;
&#xD;
        -  Neutrophil response (HI-N) (pretreatment, &lt;1.0 x 109/l) At least 100% increase and an&#xD;
           absolute increase &gt; 0.5 x 109/l&#xD;
&#xD;
        -  Progression or relapse after HI&#xD;
&#xD;
             1. At least one of the following:&#xD;
&#xD;
             2. At least 50% decrement from maximum response levels in granulocytes or platelets&#xD;
&#xD;
             3. Reduction in Hgb by ≥ 1.5 g/dl Transfusion dependence&#xD;
&#xD;
      Quality of Life (QoL) QoL will be assessed by the FACT-An score before treatment and monthly&#xD;
      during the study, at the end of each cycle of treatment. The FACT-An questionnaire will be&#xD;
      performed as outpatient interviews by one trained nurse The QoL battery, according to FACT-An&#xD;
      questionnaire, consists of items including physical, functional, emotional, social spiritual&#xD;
      symptoms&#xD;
&#xD;
      Patient evaluation&#xD;
&#xD;
        -  Physical examination (at entry and every month).&#xD;
&#xD;
        -  Peripheral blood count and differential (at entry and every two weeks).&#xD;
&#xD;
        -  Bone marrow biopsy (at entry; at the end of the 4th course; at the end of study-8th&#xD;
           course).&#xD;
&#xD;
        -  Bone marrow aspirate (at entry; at the end of the 4th course; at the end of study-8th&#xD;
           course).&#xD;
&#xD;
        -  Cytogenetics (at entry; at end of the 4th course; at the end of study -8th course).&#xD;
&#xD;
        -  Blood biochemistry profile (at entry and every month).&#xD;
&#xD;
        -  HBV, HCV, HIV (at entry).&#xD;
&#xD;
        -  Gene Profile (at entry; at the end of the 4th course; at the end of study-8th course).&#xD;
&#xD;
        -  Cytokines, Onc.M, IL6, IL11 (at entry; at the end of the 4th course; at the end of&#xD;
           study-8th course).&#xD;
&#xD;
        -  FACT-an (at entry; at the end of each course).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy (hematologic response) of five days monthly 5-Aza treatment schedule in patients with low-risk MDS (IPSS 0-1).</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the toxicity of five days monthly 5-Aza treatment schedule in patients with low-risk MDS (IPSS 0-1).</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the QoL by the FACT-An questionnaire</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacytidine</intervention_name>
    <description>Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted</description>
    <arm_group_label>Azacytidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with low-risk (IPSS 0-INT1) MDS according to WHO classification, presenting&#xD;
             one or more of the followings:&#xD;
&#xD;
               -  Symptomatic anemia requiring RBC transfusion supportive therapy previously&#xD;
                  unresponsive to EPO or not expected to respond to EPO&#xD;
&#xD;
               -  Thrombocytopenia requiring platelet transfusion with or without muco-cutaneous&#xD;
                  haemorrhagic syndrome&#xD;
&#xD;
               -  Persistent (&gt; 3 months) absolute neutrophil count less then 1,5 x 109/L, with or&#xD;
                  without infections, requiring or not myeloid growth factor therapy&#xD;
&#xD;
          -  ≥ 18 years old.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  ECOG performance Status Grade 0-2.&#xD;
&#xD;
          -  Serum bilirubin levels ≤ 1.5 upper limit of the normal (ULN)&#xD;
&#xD;
          -  Serum GOT and GPT levels ≤ 2x UNL.&#xD;
&#xD;
          -  Creatinine levels ≤ 1.5x UNL.&#xD;
&#xD;
          -  Negative serum β-human chorionic gonadotropin (β-HCG) pregnancy test 24 hours prior to&#xD;
             beginning of therapy with 5-AZA, for fertile women.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with MDS according to WHO classification with INT-2 or high IPSS risk.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months.&#xD;
&#xD;
          -  ECOG performance Status Grade &gt; 2.&#xD;
&#xD;
          -  Serum bilirubin levels &gt;1.5 upper limit of the normal (ULN).&#xD;
&#xD;
          -  Serum GOT and GPT levels &gt; 2 x UNL.&#xD;
&#xD;
          -  Creatinine levels &gt;1.5 x UNL.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Insulin-dependent diabetes and uncontrolled non insulin-dependent diabetes.&#xD;
&#xD;
          -  Severe cardiac or pulmonary disease incompatible with the conduction of the protocol.&#xD;
&#xD;
          -  Patient with a clear indication to receive long-term anticoagulant therapy.&#xD;
&#xD;
          -  Other active hematologic or solid tumors.&#xD;
&#xD;
          -  Severe CNS disease.&#xD;
&#xD;
          -  Malignant hepatic tumors.&#xD;
&#xD;
          -  Hypersensitivity to mannitol or azacitidine.&#xD;
&#xD;
          -  No written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Domenico Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair of Haematology, Brescia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Haematology, Bone Marrow Transplant Unit</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mantova</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Abdulhaq H, Rossetti JM. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. Review.</citation>
    <PMID>18042004</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Domenico Russo</investigator_full_name>
    <investigator_title>Full Professor of Hematology</investigator_title>
  </responsible_party>
  <keyword>low-risk (IPSS 0-INT1) MDS according to WHO classification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

